

SÃ©bastien L Degorce

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6930776/publications.pdf>

Version: 2024-02-01

29
papers

789
citations

516215

16
h-index

525886

27
g-index

36
all docs

36
docs citations

36
times ranked

1373
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Optimisation of a Pyrimidopyridone Series of IRAK4 Inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 63, 116729.	1.4	1
2	Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1 "DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14498-14512.	2.9	50
3	Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10460-10473.	2.9	28
4	Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115815.	1.4	5
5	Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a log <i>D</i> Lowering Twist. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1198-1204.	1.3	33
6	Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88 ^{L265P} Mutant Diffuse Large B Cell Lymphoma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9918-9930.	2.9	13
7	Tricyclic Indazoles "A Novel Class of Selective Estrogen Receptor Degradation Antagonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1593-1608.	2.9	30
8	The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 <i>H</i> -pyran-4-yl)-1,3-dihydro-2 <i>H</i> -imidazo[4,5- <i>c</i>]}) <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3823-3841.	2.9	79
9	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 913-924.	1.4	13
10	Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8934-8943.	2.9	56
11	Orally Bioavailable and Blood "Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1637-1647.	1.9	46
12	Application of Hyperpolarized ¹³ C Magnetic Resonance Imaging to Detect Target Inhibition of NFκB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. <i>Blood</i> , 2018, 132, 2840-2840.	0.6	0
13	Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4 <i>H</i> -chromen-4-one as PI3K ^{2/1} inhibitors for the treatment of PTEN-deficient tumours. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1949-1954.	1.0	4
14	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88 ^{L265P} Diffuse Large B-Cell Lymphoma. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10071-10091.	2.9	45
15	Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4859-4866.	2.9	23
16	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6281-6292.	2.9	56
17	Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3K ^{2/1} inhibitors for the treatment of PTEN-deficient tumours. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2318-2323.	1.0	7
18	Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 94-99.	1.3	33

#	ARTICLE	IF	CITATIONS
19	Synthesis of novel, functionalised tricycles utilising the interrupted Pummerer reaction. <i>Tetrahedron Letters</i> , 2016, 57, 152-154.	0.7	8
20	Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma. <i>Blood</i> , 2016, 128, 777-777.	0.6	2
21	Investigation of <i>E</i> -3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3522-3533.	2.9	40
22	Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3611-3625.	2.9	71
23	Compound Passport Service: supporting corporate collection owners in open innovation. <i>Drug Discovery Today</i> , 2015, 20, 1250-1255.	3.2	4
24	Discovery of <i>R</i> -8-(1-(3,5-Difluorophenylamino)ethyl)- <i>N,N</i> -dimethyl-2-morpholino-4-oxo-4 <i>H</i> -chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3K β and PI3K γ for the Treatment of PTEN-Deficient Cancers. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 943-962.	2.9	73
25	Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2- <i>a</i>]pyrimidine-7-carboxamides as PI3K β/γ inhibitors for the treatment of PTEN-deficient tumours. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3928-3935.	1.0	18
26	One-pot synthesis of bis(amino)-1,2,4-thiadiazoles via direct SNAr. <i>Tetrahedron Letters</i> , 2013, 54, 788-791.	0.7	6
27	Analyzing compound and project progress through multi-objective-based compound quality assessment. <i>Future Medicinal Chemistry</i> , 2013, 5, 753-767.	1.1	14
28	Facile, diversity-orientated one-pot synthesis of ethyl 1,5-disubstituted-1 <i>H</i> -1,2,4-triazole-3-carboxylates. <i>Tetrahedron Letters</i> , 2012, 53, 6078-6082.	0.7	11
29	Diversity-orientated synthesis of 3,5-bis(arylamino)pyrazoles. <i>Tetrahedron Letters</i> , 2011, 52, 6719-6722.	0.7	16